Cost-utility Analysis of Screening for Diabetic Retinopathy in Japan: A Probabilistic Markov Modeling Study
暂无分享,去创建一个
[1] Yuji Sato,et al. Transition of denture treatment for 18 years from survey of medical care activities in public health insurance , 2016 .
[2] Marie Schmidt,et al. HEAL TH AT A GLANCE , 2007 .
[3] Kai Keiko,et al. Trends in Height of Japanese According to The National Health and Nutrition Survey in Japan , 2015 .
[4] Douglas K Owens,et al. Cost-Effectiveness of Treatment of Diabetic Macular Edema , 2014, Annals of Internal Medicine.
[5] Quan Dong Nguyen,et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.
[6] B. Klein,et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.
[7] K. Pesudovs,et al. Social and emotional impact of diabetic retinopathy: a review , 2012, Clinical & experimental ophthalmology.
[8] Thomas W. Gardner,et al. The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .
[9] S. Fukuhara,et al. Cost-effectiveness of cataract surgery in Japan , 2011, Japanese Journal of Ophthalmology.
[10] Peter Bragge,et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. , 2011, Archives of ophthalmology.
[11] Y. Saeki,et al. A two-year review of vitreous surgery for proliferative diabetic retinopathy , 2010 .
[12] K. Pesudovs,et al. The impact of diabetic retinopathy: understanding the patient's perspective , 2010, British Journal of Ophthalmology.
[13] M. Alegría,et al. Valuing health in a racially and ethnically diverse community sample: an analysis using the valuation metrics of money and time , 2010, Quality of Life Research.
[14] A. Levy,et al. Patient preferences for diabetic retinopathy health States. , 2010, Investigative ophthalmology & visual science.
[15] S. Bae,et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.
[16] R. Edwards,et al. Diabetic retinopathy screening: a systematic review of the economic evidence , 2010, Diabetic medicine : a journal of the British Diabetic Association.
[17] Anthea M Burnett,et al. Global vision impairment due to uncorrected presbyopia. , 2008, Archives of ophthalmology.
[18] 山切 啓太. Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy , 2008 .
[19] Y. Tano,et al. [Survey of triamcinolone acetonide for ocular diseases in Japan]. , 2007, Nippon Ganka Gakkai zasshi.
[20] T. Oizumi. [Epidemiologic investigation on the incidence of diabetes mellitus from impaired glucose tolerance in population based study]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[21] Gary C. Brown,et al. Evidence-Based To Value-based Medicine , 2005 .
[22] M. Shimura,et al. Gliclazide Attenuates the Intracellular Ca2+ Changes Induced In Vitro by Ischemia in the Retinal Slices of Rats with Streptozotocin-Induced Diabetes , 2005, Current eye research.
[23] Y. Nose,et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study , 2004, Diabetologia.
[24] E. Agrón,et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. , 2003, Ophthalmology.
[25] H. Yamashita,et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. , 2003, American journal of ophthalmology.
[26] G. Brown,et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients , 2002, The British journal of ophthalmology.
[27] D. Feeny,et al. The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.
[28] R. Hayward,et al. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. , 2000, JAMA.
[29] A H Briggs,et al. Handling uncertainty in economic evaluations of healthcare interventions , 1999, BMJ.
[30] G. Brown,et al. Vision and quality-of-life. , 1999, Transactions of the American Ophthalmological Society.
[31] A H Briggs,et al. Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.
[32] H. Funatsu. Status of Ophthalmological Examination in Diabetics , 1997 .